Released date: June 28, 2017

Precision Medicine Impacts NSCLC Treatment

On June 22, 2017, the US FDA approved the two-drug combo of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of patients with BRAF V600E-positive, advanced or metastatic non-small cell lung cancer (NSCLC). After receiving a green-light from the EMA (February 27, 2017), this duo has now entered the US market based on Phase II study results in which more than 60% of treatment-naive and previously treated patients responded. In 2015, this combination therapy received both orphan and breakthrough designation in lung cancer and in the same year, Novartis acquired them as part of its asset-swap deal with GlaxoSmithKline.